Menu Search
Equities

Eton Pharmaceuticals Inc

ETON:NMQ

Eton Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.90
  • Today's Change-0.01 / -0.17%
  • Shares traded215.59k
  • 1 Year change+32.29%
  • Beta1.2639
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Eton Pharmaceuticals Inc grew revenues 48.90% from 21.25m to 31.64m while net income improved from a loss of 9.02m to a smaller loss of 936.00k.
Gross margin59.48%
Net profit margin-21.31%
Operating margin-20.00%
Return on assets-21.31%
Return on equity-44.30%
Return on investment-38.27%
More ▼

Cash flow in USDView more

In 2023, Eton Pharmaceuticals Inc increased its cash reserves by 31.17%, or 5.08m. The company earned 6.82m from its operations for a Cash Flow Margin of 21.54%. In addition the company used 775.00k on investing activities and also paid 957.00k in financing cash flows.
Cash flow per share-0.2212
Price/Cash flow per share--
Book value per share0.5229
Tangible book value per share0.2851
More ▼

Balance sheet in USDView more

Eton Pharmaceuticals Inc appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 21.39m.
Current ratio1.40
Quick ratio1.28
Total debt/total equity0.346
Total debt/total capital0.2571
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.